Dallas, Texas 04/01/2014 (FINANCIALSTRENDS) - Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has been one of the leading pharmaceutical company which are engaged in developing drugs for treating gastrointestinal GI.
Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ:RPTP) , Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) , KYTHERA Biopharmaceuticals Inc. (NASDAQ:KYTH) and Synergy Pharmaceuticals Inc.
Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Monday, March 17th. The company reported ($0.22) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.20) by $0.02.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) a developer of new drugs to treat gastrointestinal disorders and diseases, reported its financial results and business update for the fourth quarter and the year ended December 31, 2013.
Las Vegas, NV - April 15, 2014 - (TechSonian) �Synergy Pharmaceuticals Inc (NASDAQ:SGYP) recently reported its financial results and business update for the fourth quarter and the year ended December 31, 2013.